# US 2001/0024786 A1 · Human peroxisomal thioesterase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024786 A1
- Document ID: US20010024786A1
- Status: Published application
- Kind: A1
- Application number: 09/766,366
- Filed: 2001-01-18
- Published: 2001-09-27
- Earliest claimed: 1997-06-11
- Assignees: Incyte Pharmaceuticals, Inc.
- Inventors: Jennifer L. Hillman; Purvi Shah; Neil C. Corley
- Web page: https://patentgrep.com/patent/US20010024786A1

## CPC

- C12N 9/16: acting on ester bonds (3.1)
- A61P 3/06: Antihyperlipidemics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides a human peroxisomal thioesterase (PxTE) and polynucleotides which identify and encode PxTE. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PxTE.

## Claims

### Claim 1

A purified polypeptide comprising an amino acid sequence selected from the group consisting of:
a) an amino acid sequence of SEQ ID NO: 1,
b) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 1,
c) a biologically-active fragment of the amino acid sequence of SEQ ID NO: 1, and
d) an immunogenic fragment of the amino acid sequence of SEQ ID NO: 1.

### Claim 2 (depends on 1)

An isolated polypeptide of claim 1, having a sequence of SEQ ID NO: 1.

### Claim 3 (depends on 1)

An isolated polynucleotide encoding a polypeptide of claim 1.

### Claim 4 (depends on 2)

An isolated polynucleotide encoding a polypeptide of claim 2.

### Claim 5 (depends on 4)

An isolated polynucleotide of claim 4, having a sequence of SEQ ID NO:2.

### Claim 6 (depends on 3)

A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

### Claim 7 (depends on 6)

A cell transformed with a recombinant polynucleotide of claim 6.

### Claim 8 (depends on 1)

A method for producing a polypeptide of claim 1, the method comprising:
a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
b) recovering the polypeptide so expressed.

### Claim 9 (depends on 8)

A method of claim 8, wherein the polypeptide has the sequence of SEQ ID NO:2.

### Claim 10 (depends on 1)

An isolated antibody which specifically binds to a polypeptide of claim 1.

### Claim 11

An isolated polynucleotide comprising a sequence selected from the group consisting of:
a) a polynucleotide sequence of SEQ ID NO:2,
b) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:2,
c) a polynucleotide sequence complementary to a),
d) a polynucleotide sequence complementary to b) and
e) a ribonucleotide equivalent of a)-d).

### Claim 12 (depends on 11)

An isolated polynucleotide comprising at least 60 contiguous nucleic acids of claim 11.

### Claim 13 (depends on 11)

A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

### Claim 14 (depends on 13)

A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

### Claim 15 (depends on 11)

A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

### Claim 16 (depends on 1)

A composition comprising an effective amount of a polypeptide of claim 1 and an acceptable excipient.

### Claim 17 (depends on 16)

A composition of claim 16, wherein the polypeptide has the sequence of SEQ ID NO: 1.

### Claim 18 (depends on 1)

A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting agonist activity in the sample.

### Claim 19 (depends on 1)

A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting antagonist activity in the sample.

### Claim 20 (depends on 1)

A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence of claim 1, the method comprising:
a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
b) detecting altered expression of the target polynucleotide, and
c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

### Claim 21 (depends on 11)

A method for assessing toxicity of a test compound, said method comprising:
a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
c) quantifying the amount of hybridization complex; and
d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

### Claim 22 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO: 1.

### Claim 23 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:2.

### Claim 24 (depends on 10)

A diagnostic test for a condition or disease associated with the expression of PxTE in a biological sample comprising the steps of:
a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody: polypeptide complex; and
b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

### Claim 25 (depends on 10)

The antibody of claim 10, wherein the antibody is:
(a) a chimeric antibody;
(b) a single chain antibody;
(c) a Fab fragment;
(d) a F(ab′)2 fragment; or
(e) a humanized antibody.

### Claim 26 (depends on 10)

A composition comprising an antibody of claim 10 and an acceptable excipient.

### Claim 27 (depends on 26)

A method of diagnosing a condition or disease associated with the expression of PxTE in a subject, comprising administering to said subject an effective amount of the composition of claim 26.

### Claim 28 (depends on 26)

A composition of claim 26, wherein the antibody is labeled.

### Claim 29 (depends on 28)

A method of diagnosing a condition or disease associated with the expression of PxTE in a subject, comprising administering to said subject an effective amount of the composition of claim 28.

### Claim 30 (depends on 10)

A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:
a) immunizing an animal with a polypeptide of SEQ ID NO: I or an immunogenic fragment thereof under conditions to elicit an antibody response;
b) isolating antibodies from said animal; and
c) screening the isolated antibodies with the polypeptide thereby identifying a polyclonal antibody which binds specifically to a polypeptide of SEQ ID NO: 1.

### Claim 31 (depends on 30)

An antibody produced by a method of claim 30.

### Claim 32 (depends on 31)

A composition comprising the antibody of claim 31 and a suitable carrier.

### Claim 33 (depends on 10)

A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising:
a) immunizing an animal with a polypeptide of SEQ ID NO: 1 or an immunogenic fragment thereof under conditions to elicit an antibody response;
b) isolating antibody producing cells from the animal;
c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
d) culturing the hybridoma cells; and
e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide of SEQ ID NO: 1.

### Claim 34 (depends on 33)

A monoclonal antibody produced by a method of claim 33.

### Claim 35 (depends on 34)

A composition comprising the antibody of claim 34 and a suitable carrier.

### Claim 36 (depends on 10)

The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.

### Claim 37 (depends on 10)

The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.

### Claim 38 (depends on 10)

A method for detecting a polypeptide of SEQ ID NO: 1 in a sample comprising the steps of:
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide of SEQ ID NO: 1 in the sample.

### Claim 39 (depends on 10)

A method of purifying a polypeptide of SEQ ID NO: 1 from a sample, the method comprising:
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
b) separating the antibody from the sample and obtaining purified polypeptide of SEQ ID NO:1.
